The Motley Fool

Tempted by the Glaxo share price? Here’s what you need to know

Image source: Getty Images.

The GlaxoSmithKline (LSE: GSK) share price has achieved one of the best performances of any FTSE 100 stock this year. 

Over the past 12 months, shares in the pharmaceutical giant have yielded a total return for investors of 16.1%, outperforming the Footsie by 13.5%. 

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Following this performance, the Glaxo share price looks hugely tempting, but are the shares undervalued at current levels? Today I’m going to try and figure this out.

Dramatic turnaround

Glaxo’s CEO is almost entirely responsible for the company’s spectacular performance over the past year. Emma Walmsley was appointed group CEO after Sir Andrew Witty retired in March 2017. She inherited a firm that had a global reputation, but that lacked a strategic focus. Walmsley didn’t waste any time changing the direction of the business.

Since taking over, she’s outlined a new road map for the company’s consumer pharmaceuticals business, presided over the substantial acquisition of Tesaro and re-focused Glaxo’s research and development teams. 

The new CEO has also outlined plans to break up the business at some point in the next few years. This is something the City has been pushing for some time. 

Breakup on the cards 

After Glaxo announced the £10bn joint venture with its US rival Pfizer to combine the two groups’ consumer healthcare businesses, management revealed that when the deal is complete, it will de-merge and float the enterprise. 

The deal closed late last month. Glaxo has a 68% ownership stake with Pfizer owning the remainder. The combined entity will have sales of as much as £10bn and could yield cost savings of £500m by 2022. 

The two partners want to spin off the new business within three years of completing the deal. So, on that time frame, it looks as if the de-merger will take place in 2022. 

And when it does, it could unlock a lot of value for shareholders. Some analysts have suggested that on a sum-of-the-parts basis, the Glaxo share price is worth more than 2,000p. Unlocking value through a break-up makes it more likely that at this price target will be realised.

Unlocking value

The possibility of a break-up is the primary reason why I think the Glaxo share price could be a great addition to your portfolio.

While the stock might look quite expensive compared to the rest of the market at current levels, the break-up value suggests that anything below 2,000p is a good deal. 

The stock is currently trading at a forward P/E of 15 compared to the UK pharmaceutical average of 17. It also supports a dividend yield of 4.6%. 

Including this income, based on the assumption that the Glaxo share price will hit 2,000p by 2020, I calculate investors could pocket a return of 30% over the next three years or 10% per annum. Because the FTSE 100 has produced an average annual return of 7% for the past 10 years, this yield looks highly attractive to me.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Rupert Hargreaves owns no share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.